Herbert Loong: Report of Asian Subgroup Data of LIBRETTO431
Herbert Loong, Clinical Associate Professor at The Chinese University of Hong Kong, shared on X about a recent paper by Koichi Goto et al. published on JTO:
“Our report of Asian subgroup data of LIBRETTO431: selpercatinib vs. ChemoIO first line treatment in RET Fusion Positive NSCLC has been published in IASLC
JTOCRR. 54% of this global trial were from East Asia . Results consistent with overall population and further echos the importance of early identification through molecular profiling in Asia.
Full paper can be found here.”
Title: First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With RET Fusion–Positive NSCLC: A LIBRETTO-431 Subgroup Analysis
Authors: Koichi Goto, Herbert H. Loong, Caicun Zhou, Kazumi Nishino, Dae Ho Lee, Se-Hoon Lee, James Chih-Hsin Yang, Dan Liu, Minji Kim Uh, Hongmei Han, Tarun Puri, Aimee Bence Lin, Ying Cheng
More posts featuring Herbert Loong.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023